HK1036801A1 - Pyrrolo(2,3-d)pyrimidine compounds, composition and use there of - Google Patents
Pyrrolo(2,3-d)pyrimidine compounds, composition and use there ofInfo
- Publication number
- HK1036801A1 HK1036801A1 HK01107744A HK01107744A HK1036801A1 HK 1036801 A1 HK1036801 A1 HK 1036801A1 HK 01107744 A HK01107744 A HK 01107744A HK 01107744 A HK01107744 A HK 01107744A HK 1036801 A1 HK1036801 A1 HK 1036801A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- pyrrolo
- composition
- pyrimidine compounds
- pyrimidine
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8986698P | 1998-06-19 | 1998-06-19 | |
US10478798P | 1998-10-19 | 1998-10-19 | |
PCT/IB1999/001100 WO1999065908A1 (en) | 1998-06-19 | 1999-06-14 | PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1036801A1 true HK1036801A1 (en) | 2002-01-18 |
Family
ID=26781018
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK01107744A HK1036801A1 (en) | 1998-06-19 | 2001-11-06 | Pyrrolo(2,3-d)pyrimidine compounds, composition and use there of |
Country Status (41)
Country | Link |
---|---|
US (3) | US6610847B2 (fi) |
EP (1) | EP1087970B1 (fi) |
JP (3) | JP4666762B2 (fi) |
KR (1) | KR100415791B1 (fi) |
CN (1) | CN1128800C (fi) |
AP (1) | AP1021A (fi) |
AR (1) | AR016499A1 (fi) |
AT (1) | ATE265458T1 (fi) |
AU (1) | AU3951899A (fi) |
BG (1) | BG65119B1 (fi) |
BR (1) | BR9911365A (fi) |
CA (1) | CA2335492C (fi) |
CZ (1) | CZ20004727A3 (fi) |
DE (1) | DE69916833T2 (fi) |
DK (1) | DK1087970T3 (fi) |
EA (1) | EA005852B1 (fi) |
ES (1) | ES2219018T3 (fi) |
FR (1) | FR14C0019I2 (fi) |
GE (1) | GEP20074227B (fi) |
GT (1) | GT199900090A (fi) |
HK (1) | HK1036801A1 (fi) |
HR (1) | HRP20000885B1 (fi) |
HU (1) | HUP0102574A3 (fi) |
ID (1) | ID26698A (fi) |
IL (1) | IL139586A0 (fi) |
MA (1) | MA26654A1 (fi) |
MY (1) | MY125916A (fi) |
NO (2) | NO318784B1 (fi) |
NZ (1) | NZ518444A (fi) |
OA (1) | OA11572A (fi) |
PA (1) | PA8476001A1 (fi) |
PE (1) | PE20000698A1 (fi) |
PL (1) | PL198640B1 (fi) |
PT (1) | PT1087970E (fi) |
RS (1) | RS50087B (fi) |
SA (1) | SA99200283B1 (fi) |
SK (1) | SK286640B6 (fi) |
TN (1) | TNSN99126A1 (fi) |
TR (1) | TR200003719T2 (fi) |
TW (1) | TW505646B (fi) |
WO (1) | WO1999065908A1 (fi) |
Families Citing this family (123)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PA8474101A1 (es) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
TW505646B (en) * | 1998-06-19 | 2002-10-11 | Pfizer Prod Inc | Pyrrolo [2,3-d] pyrimidine compounds |
JP4078074B2 (ja) | 1999-12-10 | 2008-04-23 | ファイザー・プロダクツ・インク | ピロロ[2,3−d]ピリミジン化合物 |
HUP0301114A3 (en) * | 2000-06-26 | 2004-11-29 | Pfizer Prod Inc | Pyrrolo[2,3-d]pyrimidine compounds as immunosuppressive agents and pharmaceutical compositions containing them |
CA2422488A1 (en) | 2000-09-20 | 2002-03-28 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | 4-amino-quinazolines |
US7067550B2 (en) * | 2000-11-03 | 2006-06-27 | Massachusetts Institute Of Technology | Treatments for neurotoxicity in Alzheimer's Disease |
DE10063294A1 (de) * | 2000-12-19 | 2002-07-04 | Aventis Pharma Gmbh | Substituierte Heterocyclo-Norbornylamino-Derivate, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
JP2004528295A (ja) * | 2001-01-30 | 2004-09-16 | サイトピア ピーティワイ リミテッド | キナーゼ阻害方法 |
KR100639772B1 (ko) | 2001-02-12 | 2006-10-30 | 에프. 호프만-라 로슈 아게 | 6-치환된 피리도-피리미딘 |
US7301023B2 (en) | 2001-05-31 | 2007-11-27 | Pfizer Inc. | Chiral salt resolution |
GB0115393D0 (en) * | 2001-06-23 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
CA2452392A1 (en) * | 2001-06-29 | 2003-01-16 | Ab Science | Use of tyrosine kinase inhibitors for treating inflammatory bowel diseases (ibd) |
WO2003002108A2 (en) | 2001-06-29 | 2003-01-09 | Ab Science | Use of tyrosine kinase inhibitors for treating inflammatory diseases |
DE60216281T2 (de) | 2001-06-29 | 2007-07-05 | Ab Science | Die verwendung von tyrosinkinasehemmer zur behandlung von allergischen erkrankungen |
US7727731B2 (en) | 2001-06-29 | 2010-06-01 | Ab Science | Potent, selective and non toxic c-kit inhibitors |
WO2003002109A2 (en) * | 2001-06-29 | 2003-01-09 | Ab Science | Use of tyrosine kinase inhibitors for treating autoimmune diseases |
GB0119249D0 (en) | 2001-08-07 | 2001-10-03 | Novartis Ag | Organic compounds |
US7323469B2 (en) | 2001-08-07 | 2008-01-29 | Novartis Ag | 7H-pyrrolo[2,3-d]pyrimidine derivatives |
US7829566B2 (en) | 2001-09-17 | 2010-11-09 | Werner Mederski | 4-amino-quinazolines |
GT200200234A (es) | 2001-12-06 | 2003-06-27 | Compuestos cristalinos novedosos | |
ES2305435T3 (es) | 2002-01-10 | 2008-11-01 | Bayer Healthcare Ag | Inhibidores de la rho-quinasa. |
MXPA04007191A (es) | 2002-01-23 | 2005-03-31 | Bayer Pharmaceuticals Corp | Derivados de pirimidina como inhibidores de rho-quinasa. |
CA2473910C (en) | 2002-01-23 | 2011-03-15 | Bayer Pharmaceuticals Corporation | Pyrimidine derivatives as rho-kinase inhibitors |
GB0202679D0 (en) * | 2002-02-05 | 2002-03-20 | Glaxo Group Ltd | Novel compounds |
EP1388541A1 (en) | 2002-08-09 | 2004-02-11 | Centre National De La Recherche Scientifique (Cnrs) | Pyrrolopyrazines as kinase inhibitors |
BR0316487A (pt) * | 2002-11-26 | 2005-10-11 | Pfizer Prod Inc | Método todo de tratamento da rejeição de transplantes |
US7169918B2 (en) * | 2003-10-27 | 2007-01-30 | Genelabs Technologies, Inc. | Methods for preparing 7-(2′-substituted-β-D-ribofuranosyl)-4-(NR2R3)-5-(substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine derivatives |
EP1689407A1 (en) * | 2003-11-25 | 2006-08-16 | Pfizer Products Inc. | Method of treatment of atherosclerosis |
BRPI0509299A (pt) * | 2004-03-30 | 2007-09-18 | Taisho Pharmaceutical Co Ltd | composto ou um sal, hidrato, ou solvato farmaceuticamente aceitável do mesmo, composição farmacêutica, e, métodos para a profilaxia ou o tratamento de doença, para reduzir ingestão de alimento de um indivìduo, para induzir saciedade em um indivìduo, para controlar ou reduzir ganho de peso em um indivìduo, para modular um receptor de mch em um indivìduo e para produzir uma composição farmacêutica |
CA2571710A1 (en) | 2004-06-24 | 2006-11-02 | Nicholas Valiante | Small molecule immunopotentiators and assays for their detection |
WO2006004703A2 (en) * | 2004-06-29 | 2006-01-12 | Amgen Inc. | PYRROLO[2,3-d]PYRIMIDINES THAT MODULATE ACK1 AND LCK ACTIVITY |
CA2575808A1 (en) | 2004-08-02 | 2006-02-16 | Osi Pharmaceuticals, Inc. | Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds |
MY179032A (en) | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
AR054416A1 (es) | 2004-12-22 | 2007-06-27 | Incyte Corp | Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas. |
US7423043B2 (en) * | 2005-02-18 | 2008-09-09 | Lexicon Pharmaceuticals, Inc. | 4-Piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine compounds |
EP1891066B1 (en) | 2005-05-13 | 2010-12-22 | Irm, Llc | Compounds and compositions as protein kinase inhibitors |
EP2251341A1 (en) | 2005-07-14 | 2010-11-17 | Astellas Pharma Inc. | Heterocyclic Janus kinase 3 inhibitors |
JP5071374B2 (ja) | 2005-07-14 | 2012-11-14 | アステラス製薬株式会社 | ヘテロ環ヤヌスキナーゼ3阻害剤 |
EP2270014A1 (en) | 2005-09-22 | 2011-01-05 | Incyte Corporation | Azepine inhibitors of janus kinases |
WO2007041130A2 (en) * | 2005-09-30 | 2007-04-12 | Vertex Pharmaceuticals Incorporated | Deazapurines useful as inhibitors of janus kinases |
MY159449A (en) | 2005-12-13 | 2017-01-13 | Incyte Holdings Corp | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
US20100273776A1 (en) * | 2006-03-29 | 2010-10-28 | FOLDRx PHARMACEUTICALS, INC | Inhibition of alpha-synuclein toxicity |
EP2043655A2 (en) | 2006-04-25 | 2009-04-08 | Astex Therapeutics Limited | Purine and deazapurine derivatives as pharmaceutical compounds |
CA2673038C (en) | 2006-12-22 | 2015-12-15 | Incyte Corporation | Substituted tricyclic heteroaryl compounds as janus kinase inhibitors |
US20100105661A1 (en) | 2007-01-12 | 2010-04-29 | Astellas Pharma Inc. | Condensed pyridine compound |
RU2009140319A (ru) * | 2007-04-02 | 2011-05-10 | Палау Фарма С.А. (Es) | Производные пирролпиримидина |
CL2008001709A1 (es) | 2007-06-13 | 2008-11-03 | Incyte Corp | Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras. |
TR201903488T4 (tr) | 2007-06-13 | 2019-04-22 | Incyte Holdings Corp | Janus kinaz inhibitörü (r)-3-(4-(7h-pirolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)-3-siklopentilpropannitril tuzlarının kullanımı. |
DE102007027800A1 (de) | 2007-06-16 | 2008-12-18 | Bayer Healthcare Ag | Substituierte bicyclische Heteroaryl-Verbindungen und ihre Verwendung |
BRPI0817402A2 (pt) * | 2007-11-10 | 2019-09-24 | Landmark Graphics Corp A Halliburton Company | dispositivos e métodos para automação de fluxos de trabalho, adaptação e integração |
EP3912973A3 (en) * | 2007-11-28 | 2022-02-16 | Dana-Farber Cancer Institute, Inc. | Small molecule myristate inhibitors of bcr-abl and methods of use |
CN101981036B (zh) | 2008-02-06 | 2013-09-04 | 诺瓦提斯公司 | 吡咯并[2,3-d]嘧啶及其作为酪氨酸激酶抑制剂的用途 |
PL2247592T3 (pl) * | 2008-02-25 | 2012-01-31 | Hoffmann La Roche | Pirolopirazynowe inhibitory kinazy |
UA101493C2 (ru) | 2008-03-11 | 2013-04-10 | Инсайт Корпорейшн | Производные азетидина и циклобутана как ингибиторы jak |
WO2009115084A2 (de) * | 2008-03-20 | 2009-09-24 | Schebo Biotech Ag | Neue pyrrolopyrimidin-derivate und deren verwendungen |
AU2009266806A1 (en) * | 2008-07-03 | 2010-01-07 | Exelixis Inc. | CDK modulators |
CA2732628A1 (en) * | 2008-08-01 | 2010-02-04 | Biocryst Pharmaceuticals, Inc. | Therapeutic agents |
RS53382B (en) | 2008-08-20 | 2014-10-31 | Zoetis Llc | PIROL [2,3-D] PIRIMIDINE COMPOUNDS |
US8385364B2 (en) * | 2008-09-24 | 2013-02-26 | Nec Laboratories America, Inc. | Distributed message-passing based resource allocation in wireless systems |
AU2010239396B2 (en) * | 2009-04-20 | 2016-06-23 | Auspex Pharmaceuticals, Llc | Piperidine inhibitors of Janus Kinase 3 |
WO2010135650A1 (en) | 2009-05-22 | 2010-11-25 | Incyte Corporation | N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS |
AR076920A1 (es) | 2009-05-22 | 2011-07-20 | Incyte Corp | 3-(4-(7h-pirrolo(2,3-d)pirimidin-4-il)-1h-pirazol-1-il)octano-o heptano--nitrilo como inhibidores de jak |
CN102574857B (zh) * | 2009-07-08 | 2015-06-10 | 利奥制药有限公司 | 作为jak受体和蛋白酪氨酸激酶抑制剂的杂环化合物 |
TWI466885B (zh) | 2009-07-31 | 2015-01-01 | Japan Tobacco Inc | 含氮螺環化合物及其醫藥用途 |
TW201111385A (en) * | 2009-08-27 | 2011-04-01 | Biocryst Pharm Inc | Heterocyclic compounds as janus kinase inhibitors |
AR078012A1 (es) | 2009-09-01 | 2011-10-05 | Incyte Corp | Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus |
WO2011044481A1 (en) | 2009-10-09 | 2011-04-14 | Incyte Corporation | Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
EP2488524B1 (en) | 2009-10-15 | 2013-07-03 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidine compounds |
ES2461967T3 (es) | 2009-12-18 | 2014-05-21 | Pfizer Inc. | Compuestos de pirrolo[2,3-d]pirimidina |
AU2011213198B2 (en) | 2010-02-05 | 2014-04-24 | Zoetis Llc | Pyrrolo [ 2,3-d] pyrimidine urea compounds as JAK inhibitors |
EP2360158A1 (en) * | 2010-02-18 | 2011-08-24 | Almirall, S.A. | Pyrazole derivatives as jak inhibitors |
PT3050882T (pt) | 2010-03-10 | 2018-04-16 | Incyte Holdings Corp | Derivados de piperidin-4-ilazetidina como inibidores de jak1 |
EP2590981B1 (en) * | 2010-07-09 | 2014-09-03 | Leo Pharma A/S | Novel homopiperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof |
AU2011329734B2 (en) | 2010-11-19 | 2015-05-28 | Incyte Holdings Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
CA2818545C (en) | 2010-11-19 | 2019-04-16 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors |
JP2014501772A (ja) | 2011-01-07 | 2014-01-23 | レオ ファーマ アクティーゼルスカブ | タンパク質チロシンキナーゼ阻害薬としての新規スルファミドピペラジン誘導体およびその医薬用途 |
PT2675451E (pt) | 2011-02-18 | 2015-10-16 | Incyte Corp | Terapia de combinação com inibidores mtor/jak |
EP2688890B1 (en) | 2011-03-22 | 2017-08-30 | Advinus Therapeutics Limited | Substituted fused tricyclic compounds, compositions and medicinal applications thereof |
AU2012255792A1 (en) * | 2011-05-17 | 2013-11-07 | Principia Biopharma Inc. | Azaindole derivatives as tyrosine kinase inhibitors |
ES2560611T3 (es) | 2011-06-20 | 2016-02-22 | Incyte Holdings Corporation | Derivados de fenil de azetidinilo, carboxamida de piridilo o pirazinilo como inhibidores de JAK |
CA2844507A1 (en) | 2011-08-10 | 2013-02-14 | Novartis Pharma Ag | Jak pi3k/mtor combination therapy |
TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
CA2856722C (en) | 2011-11-30 | 2022-11-22 | Emory University | Antiviral jak inhibitors useful in treating or preventing retroviral and other viral infections |
ES2682755T3 (es) * | 2011-12-21 | 2018-09-21 | Jiangsu Hengrui Medicine Co. Ltd. | Derivado del anillo heteroarilo de seis miembros de pirrol, método de preparación del mismo y sus usos medicinales |
TW201406761A (zh) | 2012-05-18 | 2014-02-16 | Incyte Corp | 做爲jak抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物 |
EP2852595B1 (en) | 2012-05-21 | 2016-06-22 | Bayer Pharma Aktiengesellschaft | Substituted benzothienopyrimidines |
JP6189948B2 (ja) * | 2012-06-29 | 2017-08-30 | ファイザー・インク | LRRK2阻害薬としての新規な4−(置換アミノ)−7H−ピロロ[2,3−d]ピリミジン |
TWI574946B (zh) * | 2012-07-17 | 2017-03-21 | 葛蘭素史密斯克藍智慧財產權有限公司 | 化合物 |
ES2707627T3 (es) * | 2012-07-20 | 2019-04-04 | Zoetis Services Llc | Régimen de dosificación para inhibidores de Janus Quinasa (JAK) |
TW201412740A (zh) * | 2012-09-20 | 2014-04-01 | Bayer Pharma AG | 經取代之吡咯并嘧啶胺基苯并噻唑酮 |
WO2014045305A1 (en) | 2012-09-21 | 2014-03-27 | Advinus Therapeutics Limited | Substituted fused tricyclic compounds, compositions and medicinal applications thereof |
CN102936251A (zh) * | 2012-11-05 | 2013-02-20 | 上海毕得医药科技有限公司 | 一种吡咯并[2,3-d]嘧啶衍生物的制备方法 |
BR112015010663B1 (pt) | 2012-11-15 | 2022-12-06 | Incyte Holdings Corporation | Formas de dosagem oral de liberação sustentada, e uso de ruxolitinib ou de sal farmaceuticamente aceitável do mesmo |
KR101683061B1 (ko) * | 2013-02-07 | 2016-12-07 | 한국과학기술연구원 | JAK-3 저해제로 유용한 7H-피롤로[2,3-d]피리미딘-4-싸이올 유도체 |
TR201902525T4 (tr) | 2013-02-22 | 2019-03-21 | Pfizer | Janus ile alakalı kinazların (jak) inhibitörleri olarak bir veya daha fazla ilave ajan ile pirolo [2,3-d]pirimidin türevlerinin kombinasyonu. |
UA121532C2 (uk) | 2013-03-06 | 2020-06-10 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки при отриманні інгібітора jak |
WO2014139388A1 (en) * | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
EP3721873A1 (en) | 2013-08-07 | 2020-10-14 | Incyte Corporation | Sustained release dosage forms for a jak1 inhibitor |
KR101930603B1 (ko) | 2013-12-05 | 2018-12-18 | 화이자 인코포레이티드 | 피롤로[2,3-d]피리미디닐, 피롤로[2,3-b]피라지닐 및 피롤로[2,3-d]피리디닐 아크릴아미드 |
US9695171B2 (en) | 2013-12-17 | 2017-07-04 | Pfizer Inc. | 3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors |
US9498467B2 (en) | 2014-05-30 | 2016-11-22 | Incyte Corporation | Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1 |
JP6585158B2 (ja) | 2014-08-12 | 2019-10-02 | ファイザー・インク | ヤヌスキナーゼの阻害に有用なピロロ[2,3−d]ピリミジン誘導体 |
JP6761815B2 (ja) | 2015-05-01 | 2020-09-30 | ファイザー・インク | ピロロ[2,3−d]ピリミジニル、ピロロ[2,3−b]ピラジニル、ピロロ[2,3−b]ピリジニルアクリルアミド、およびそのエポキシド |
PT3305788T (pt) * | 2015-05-29 | 2020-09-25 | Wuxi Fortune Pharmaceutical Co Ltd | Inibidor da janus cinase |
KR101771219B1 (ko) * | 2015-08-21 | 2017-09-05 | 양지화학 주식회사 | 야누스 키나제 1 선택적 억제제 및 그 의약 용도 |
RU2722149C1 (ru) | 2015-09-14 | 2020-05-27 | Пфайзер Инк. | Новые производные имидазо[4,5-c] хинолинов и имидазо[4,5-c][1,5] нафтиридинов в качестве ингибиторов LRRK2 |
CN106831779B (zh) * | 2015-11-28 | 2019-07-19 | 南昌弘益药业有限公司 | 一类jak激酶抑制剂的新化合物 |
EP3416965B1 (en) | 2016-02-16 | 2020-10-07 | Zoetis Services LLC | Process for preparing 7h-pyrrolo [2,3-d]pyrimidine compounds |
CN107098908B (zh) * | 2016-02-23 | 2021-01-08 | 欣凯医药科技(上海)有限公司 | 一种吡咯并嘧啶类化合物的制备方法和应用 |
CN110062754B (zh) | 2016-12-14 | 2024-01-02 | 英特维特国际股份有限公司 | 作为选择性Janus激酶抑制剂的氨基吡唑类化合物 |
EP3877389A4 (en) * | 2018-11-05 | 2022-07-13 | Avista Pharma Solutions, Inc. | CHEMICAL COMPOUNDS |
US11174263B2 (en) | 2018-12-31 | 2021-11-16 | Biomea Fusion, Inc. | Inhibitors of menin-MLL interaction |
BR112021011578A2 (pt) | 2018-12-31 | 2021-08-31 | Biomea Fusion, Llc | Inibidores irreversíveis de interação menina-mll |
CN113993585A (zh) | 2019-03-27 | 2022-01-28 | 英矽智能科技知识产权有限公司 | 双环jak抑制剂及其用途 |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
JP2023554665A (ja) | 2020-12-18 | 2023-12-28 | ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド | ホウ素含有ピラゾール化合物、それらを含む組成物、それらの方法及び使用 |
JP2024534014A (ja) | 2021-08-20 | 2024-09-18 | バイオメア フュージョン,インコーポレイテッド | 癌の処置のための不可逆的メニン-MLL阻害剤、N-[4-[4-(4-モルホリニル)-7H-ピロロ[2,3-d]ピリミジン-6-イル]フェニル]-4-[[3(R)-[(1-オキソ-2-プロペン-1-イル)アミノ]-1-ピペリジニル]メチル]-2-ピリジンカルボキサミドの結晶形態 |
WO2023029943A1 (zh) * | 2021-09-03 | 2023-03-09 | 星药科技(北京)有限公司 | 一种芳杂环化合物及其制备方法和用途 |
WO2023055731A1 (en) * | 2021-09-28 | 2023-04-06 | Sanford Burnham Prebys Medical Discovery Institute | Inhibitors of serine/threonine protein kinase stk3 or stk4 and uses thereof |
KR20240124925A (ko) | 2021-12-24 | 2024-08-19 | 인터벳 인터내셔널 비.브이. | 아미노피라졸 화합물의 용도 |
GB202215117D0 (en) * | 2022-10-13 | 2022-11-30 | Norwegian Univ Sci & Tech Ntnu | Compound |
GB202215132D0 (en) * | 2022-10-13 | 2022-11-30 | Norwegian Univ Sci & Tech Ntnu | Compound |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3037980A (en) | 1955-08-18 | 1962-06-05 | Burroughs Wellcome Co | Pyrrolopyrimidine vasodilators and method of making them |
GB915303A (en) | 1958-03-13 | 1963-01-09 | Wellcome Found | Pyrrolo[2,3-d]pyrimidine derivatives and the manufacture thereof |
US6136595A (en) | 1993-07-29 | 2000-10-24 | St. Jude Children's Research Hospital | Jak kinases and regulations of cytokine signal transduction |
US5389509A (en) | 1993-10-04 | 1995-02-14 | Eastman Kodak Company | Ultrathin high chloride tabular grain emulsions |
IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
DE59500788D1 (de) * | 1994-05-03 | 1997-11-20 | Ciba Geigy Ag | Pyrrolopyrimidinderivate mit antiproliferativer Wirkung |
MX9709867A (es) * | 1995-06-07 | 1998-03-31 | Pfizer | Derivados de pirimidina condensados con un anillo heterociclico, composiciones que contienen los mismos, y uso de los mismos. |
EP0836602B1 (en) | 1995-07-05 | 2002-01-30 | E.I. Du Pont De Nemours And Company | Fungicidal pyrimidinones |
PT836605E (pt) * | 1995-07-06 | 2002-07-31 | Novartis Ag | Pirrolopirimidinas e processos para a sua preparacao |
AR004010A1 (es) | 1995-10-11 | 1998-09-30 | Glaxo Group Ltd | Compuestos heterociclicos |
WO1997018212A1 (en) | 1995-11-14 | 1997-05-22 | Pharmacia & Upjohn S.P.A. | Aryl and heteroaryl purine compounds |
WO1997027199A1 (en) | 1996-01-23 | 1997-07-31 | Novartis Ag | Pyrrolopyrimidines and processes for their preparation |
CH690773A5 (de) | 1996-02-01 | 2001-01-15 | Novartis Ag | Pyrrolo(2,3-d)pyrimide und ihre Verwendung. |
GB9604361D0 (en) * | 1996-02-29 | 1996-05-01 | Pharmacia Spa | 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors |
WO1997032879A1 (de) | 1996-03-06 | 1997-09-12 | Novartis Ag | 7-ALKYL-PYRROLO[2,3-d]PYRIMIDINE |
WO1997049706A1 (en) | 1996-06-25 | 1997-12-31 | Novartis Ag | SUBSTITUTED 7-AMINO-PYRROLO[3,2-d]PYRIMIDINES AND THE USE THEREOF |
HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
EP0912572B1 (en) | 1996-07-13 | 2003-01-15 | Glaxo Group Limited | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors |
ATE384062T1 (de) | 1996-08-23 | 2008-02-15 | Novartis Pharma Gmbh | Substituierte pyrrolopyrimidine und verfahren zu ihrer herstellung |
US6413971B1 (en) * | 1996-11-27 | 2002-07-02 | Pfizer Inc | Fused bicyclic pyrimidine derivatives |
EP0964864B1 (en) | 1997-02-05 | 2008-04-09 | Warner-Lambert Company LLC | Pyrido 2,3-d pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation |
US6187552B1 (en) | 1997-03-24 | 2001-02-13 | Pharmacia & Upjohn Company | Method for identifying inhibitors of JAK2/cytokine receptor binding |
US6080847A (en) * | 1997-12-04 | 2000-06-27 | Incyte Pharmaceuticals, Inc. | Proteins associated with cell proliferation |
WO1999051599A1 (en) | 1998-04-02 | 1999-10-14 | Neurogen Corporation | Aminoalkyl substituted pyrrolo[2,3-b]pyridine and pyrrolo[2,3-d]pyrimidine derivatives: modulators of crf1 receptors |
CA2333392A1 (en) | 1998-05-28 | 1999-12-02 | Parker Hughes Institute | Quinazolines for treating brain tumor |
TW505646B (en) * | 1998-06-19 | 2002-10-11 | Pfizer Prod Inc | Pyrrolo [2,3-d] pyrimidine compounds |
EP1091739A1 (en) | 1998-06-30 | 2001-04-18 | Parker Hughes Institute | Method for inhibiting c-jun expression using jak-3 inhibitors |
AU5682799A (en) | 1998-08-21 | 2000-03-14 | Parker Hughes Institute | Quinazoline derivatives |
US6080747A (en) | 1999-03-05 | 2000-06-27 | Hughes Institute | JAK-3 inhibitors for treating allergic disorders |
JP4078074B2 (ja) * | 1999-12-10 | 2008-04-23 | ファイザー・プロダクツ・インク | ピロロ[2,3−d]ピリミジン化合物 |
HUP0301114A3 (en) * | 2000-06-26 | 2004-11-29 | Pfizer Prod Inc | Pyrrolo[2,3-d]pyrimidine compounds as immunosuppressive agents and pharmaceutical compositions containing them |
AU2009100870A4 (en) | 2008-10-01 | 2009-10-22 | Rock Tone Enterprise Co., Ltd. | Drive mechanism for dehydrator |
TWM358618U (en) | 2008-12-26 | 2009-06-11 | Rock Tone Entpr Co Ltd | Combination structure of mop holder and cleaning body |
-
1999
- 1999-06-14 TW TW088109926A patent/TW505646B/zh active
- 1999-06-14 JP JP2000554733A patent/JP4666762B2/ja not_active Expired - Lifetime
- 1999-06-14 OA OA1200000349A patent/OA11572A/en unknown
- 1999-06-14 AT AT99922454T patent/ATE265458T1/de not_active IP Right Cessation
- 1999-06-14 IL IL13958699A patent/IL139586A0/xx active Protection Beyond IP Right Term
- 1999-06-14 CZ CZ20004727A patent/CZ20004727A3/cs unknown
- 1999-06-14 RS YUP-785/00A patent/RS50087B/sr unknown
- 1999-06-14 TR TR2000/03719T patent/TR200003719T2/xx unknown
- 1999-06-14 SK SK1898-2000A patent/SK286640B6/sk not_active IP Right Cessation
- 1999-06-14 EP EP99922454A patent/EP1087970B1/en not_active Expired - Lifetime
- 1999-06-14 CN CN99807521A patent/CN1128800C/zh not_active Ceased
- 1999-06-14 DK DK99922454T patent/DK1087970T3/da active
- 1999-06-14 KR KR10-2000-7014402A patent/KR100415791B1/ko not_active IP Right Cessation
- 1999-06-14 HU HU0102574A patent/HUP0102574A3/hu unknown
- 1999-06-14 EA EA200001203A patent/EA005852B1/ru not_active IP Right Cessation
- 1999-06-14 AU AU39518/99A patent/AU3951899A/en not_active Abandoned
- 1999-06-14 ES ES99922454T patent/ES2219018T3/es not_active Expired - Lifetime
- 1999-06-14 ID IDW20002644A patent/ID26698A/id unknown
- 1999-06-14 PL PL345123A patent/PL198640B1/pl unknown
- 1999-06-14 BR BR9911365-1A patent/BR9911365A/pt not_active Application Discontinuation
- 1999-06-14 PT PT99922454T patent/PT1087970E/pt unknown
- 1999-06-14 WO PCT/IB1999/001100 patent/WO1999065908A1/en active IP Right Grant
- 1999-06-14 DE DE69916833T patent/DE69916833T2/de not_active Expired - Lifetime
- 1999-06-14 CA CA002335492A patent/CA2335492C/en not_active Expired - Lifetime
- 1999-06-16 TN TNTNSN99126A patent/TNSN99126A1/fr unknown
- 1999-06-16 PE PE1999000531A patent/PE20000698A1/es not_active Application Discontinuation
- 1999-06-16 MA MA25630A patent/MA26654A1/fr unknown
- 1999-06-16 PA PA19998476001A patent/PA8476001A1/es unknown
- 1999-06-17 AP APAP/P/1999/001584A patent/AP1021A/en active
- 1999-06-17 AR ARP990102916A patent/AR016499A1/es active IP Right Grant
- 1999-06-17 MY MYPI99002502A patent/MY125916A/en unknown
- 1999-06-18 GT GT199900090A patent/GT199900090A/es unknown
- 1999-06-28 SA SA99200283A patent/SA99200283B1/ar unknown
-
2000
- 2000-11-08 NZ NZ518444A patent/NZ518444A/en not_active Application Discontinuation
- 2000-12-18 NO NO20006453A patent/NO318784B1/no not_active IP Right Cessation
- 2000-12-19 HR HR20000885A patent/HRP20000885B1/xx not_active IP Right Cessation
-
2001
- 2001-01-08 BG BG105129A patent/BG65119B1/bg unknown
- 2001-09-19 US US09/956,645 patent/US6610847B2/en not_active Expired - Lifetime
- 2001-11-06 HK HK01107744A patent/HK1036801A1/xx not_active IP Right Cessation
-
2003
- 2003-05-20 US US10/442,807 patent/US6890929B2/en not_active Expired - Lifetime
-
2005
- 2005-02-23 US US11/064,873 patent/US7687507B2/en not_active Expired - Fee Related
-
2007
- 2007-04-25 GE GEAP200710007A patent/GEP20074227B/en unknown
- 2007-08-06 JP JP2007204429A patent/JP4971068B2/ja not_active Expired - Lifetime
-
2011
- 2011-11-11 JP JP2011247593A patent/JP2012041365A/ja active Pending
-
2014
- 2014-03-07 FR FR14C0019C patent/FR14C0019I2/fr active Active
- 2014-05-13 NO NO2014012C patent/NO2014012I1/no not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1036801A1 (en) | Pyrrolo(2,3-d)pyrimidine compounds, composition and use there of | |
HK1036800A1 (en) | Pyrrolo(2,3-d)pyrimidine compounds, its composition and use thereof | |
HUP0103836A3 (en) | Pyrrolo[2,3d]pyrimidine compositions and their use | |
PT1382339E (pt) | Composições que contêm derivados de pirrolo[2,3-d]- pirimidina | |
HUP0102187A3 (en) | Azolo triazines and pyrimidines, pharmaceutical compositions containing them and use of the compounds | |
HK1039933A1 (en) | Novel triazolo(4,5-d)pyrimidine compounds | |
HUP0301114A3 (en) | Pyrrolo[2,3-d]pyrimidine compounds as immunosuppressive agents and pharmaceutical compositions containing them | |
SI0891978T1 (en) | 5H-Thiazolo (3,2-a) pyrimidine derivatives | |
HUP0100328A3 (en) | Novel triazolo(4,5-d)pyrimidine compounds, and pharmaceutical compositions containing the compounds | |
AU5491699A (en) | Process for the preparation of pyrrolo(2,3-d)pyrimidines | |
IL131618A0 (en) | 5,7-Disubstituted aminopyrido [2,3-D] pyrimidine compounds and their use as adenosine kinase inhibitors | |
IL130180A0 (en) | Substituted pyrimidine compounds and their use | |
IL150163A (en) | PHARMACEUTICAL COMPOSITIONS COMPRISING PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AND SOME NOVEL SUCH COMPOUNDS | |
AU2002215979A1 (en) | Use of pyrazolo(4,3-D)pyrimidines | |
PL361890A1 (en) | Use of pyrazolo[4,3-d]pyrimidines | |
ZA982912B (en) | 6,7-disubstituted-4-aminopyrido [2,3-d] pyrimidine compounds | |
ZA983175B (en) | 5, 6, 7-Trisubstituted-4-aminopyrido (2, 3-d) pyrimidine compounds | |
SI1087970T1 (en) | PYRROLO 2,3-d)PYRIMIDINE COMPOUNDS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PF | Patent in force | ||
PE | Patent expired |
Effective date: 20190613 |